Naringenin suppresses K562 human leukemia cell proliferation and ameliorates Adriamycin-induced oxidative damage in polymorphonuclear leukocytes

Li,Rui‑Fang; Feng,Ying‑Qian; Chen,Jun‑Hui; Ge,Lin‑Tong; Xiao,Shu‑Yuan; Zuo,Xue‑Lan

doi:10.3892/etm.2015.2185

Naringenin suppresses K562 human leukemia cell proliferation and ameliorates Adriamycin-induced oxidative damage in polymorphonuclear leukocytes

Authors:
- Rui‑Fang Li
- Ying‑Qian Feng
- Jun‑Hui Chen
- Lin‑Tong Ge
- Shu‑Yuan Xiao
- Xue‑Lan Zuo
View Affiliations

Affiliations: Department of Neurology, Hubei Zhongshan Hospital, Wuhan, Hubei 430033, P.R. China, Department of Endocrinology, Weapon Industry 521 Hospital, Xi'an, Shaanxi 710065, P.R. China, Department of Science and Education, Hubei Zhongshan Hospital, Wuhan, Hubei 430033, P.R. China, Department of Pathology, Biological Sciences Division, The University of Chicago, Chicago, IL 60637, USA, Department of Hematology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430071, P.R. China
Published online on: January 16, 2015 https://doi.org/10.3892/etm.2015.2185
Pages: 697-706
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Treatments for leukemia remain unsatisfactory. Conventional chemotherapy agents that aim to kill tumor cells may also damage normal cells and thus result in severe side‑effects. Naringenin, a natural polyphenolic compound with antioxidant effects, has been revealed to have significant antitumor effects with low toxicity in preliminary studies. Thus, it is considered as one of the most promising flavonoids in the treatment of leukemia. In the present study, the effects of naringenin on the K562 human leukemia cell line and the underlying mechanisms were explored in vitro. In addition, human peripheral blood polymorphonuclear leukocytes (PMNs) were used as a normal control in order to evaluate the effects of naringenin on normal granulocytes and in the mediation of Adriamycin (ADM)‑induced oxidative damage. The results revealed that K562 proliferation was significantly inhibited by naringenin in a time‑ and concentration‑dependent manner; however, minimal cytotoxic effects were observed in PMNs when naringenin was used at concentrations <400 µmol/l. Morphological changes indicative of apoptosis were observed in naringenin‑treated K562 cells. Flow cytometric analysis indicated that the K562 cells were arrested in the G0/G1 phase of the cell cycle with a significantly upregulated rate of apoptosis. Furthermore, in the naringenin‑treated K562 cells, the labeling index of proliferating cell nuclear antigen was observed to be increased by immunochemical staining, the mRNA and protein expression levels of p21/WAF1 were strongly upregulated in reverse transcription‑polymerase chain reaction and western blot analyses, whereas p53 gene expression was not significantly changed. In PMNs to which naringenin (50~80 µmol/l) was added 1 h subsequent to ADM, the cell damage induced by ADM was significantly reduced, coincident with reductions in the levels of reactive oxygen species (ROS) and malondialdehyde (MDA) and increases in the activity of superoxide dismutase and glutathione peroxidase. However, the cytotoxic effect of ADM in K562 cells was not significantly altered by naringenin, and the oxidative stress indices in K562 cells remained stable. In conclusion, the present study revealed the promising value of naringenin in leukemia treatment. Naringenin demonstrated a significant inhibitory effect on the growth of K562 cells but not on normal PMNs. Furthermore, naringenin protected PMNs from ADM‑induced oxidative damage at low concentrations. Cell cycle arrest and apoptosis‑inducing effects, achieved through p53‑independent p21/WAF1 upregulation, are likely to be the mechanism of the antileukemic effects of naringenin, and the protective effect against ADM chemotherapy‑induced damage in PMNs may be due to the antioxidant capability of this agent at low concentrations.

View Figures

View References

1	Yang C and Zhang X: Incidence survey of leukemia in China. Chin Med Sci J. 6:65–70. 1991.PubMed/NCBI
2	Friesen C, Herr I, Krammer PH and Debatin KM: Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat Med. 2:574–577. 1996. View Article : Google Scholar : PubMed/NCBI
3	Durgo K, Koncar M, Komes D, et al: Cytotoxicity of blended versus single medicinal mushroom extracts on human cancer cell lines: contribution of polyphenol and polysaccharide content. Int J Med Mushrooms. 15:435–448. 2013. View Article : Google Scholar : PubMed/NCBI
4	Ravishankar D, Rajora AK, Greco F and Osborn HM: Flavonoids as prospective compounds for anti-cancer therapy. Int J Biochem Cell Biol. 45:2821–2831. 2013. View Article : Google Scholar : PubMed/NCBI
5	Ameer B, Weintraub RA, Johnson JV, Yost RA and Rouseff RL: Flavanone absorption after naringin, hesperidin, and citrus administration. Clin Pharmacol Ther. 60:34–40. 1996. View Article : Google Scholar : PubMed/NCBI
6	Galati G, Chan T, Wu B and O’Brien PJ: Glutathione-dependent generation of reactive oxygen species by the peroxidase-catalyzed redox cycling of flavonoids. Chem Res Toxicol. 12:521–525. 1999. View Article : Google Scholar : PubMed/NCBI
7	Shi Y, Dai J, Liu H, et al: Naringenin inhibits allergen-induced airway inflammation and airway responsiveness and inhibits NF-kappaB activity in a murine model of asthma. Can J Physiol Pharmacol. 87:729–735. 2009. View Article : Google Scholar : PubMed/NCBI
8	Arul D and Subramanian P: Inhibitory effect of naringenin (citrus flavonone) on N-nitrosodiethylamine induced hepatocarcinogenesis in rats. Biochem Biophys Res Commun. 434:203–209. 2013. View Article : Google Scholar : PubMed/NCBI
9	Lv Y, Zhang B, Xing G, Wang F and Hu Z: Protective effect of naringenin against acetaminophen-induced acute liver injury in metallothionein (MT)-null mice. Food Funct. 4:297–302. 2013. View Article : Google Scholar
10	Tsai SJ, Huang CS, Mong MC, Kam WY, Huang HY and Yin MC: Anti-inflammatory and antifibrotic effects of naringenin in diabetic mice. J Agric Food Chem. 60:514–521. 2012. View Article : Google Scholar
11	Andrade JE and Burgess JR: Effect of the citrus flavanone naringenin on oxidative stress in rats. J Agric Food Chem. 55:2142–2148. 2007. View Article : Google Scholar : PubMed/NCBI
12	Lee S, Lee CH, Moon SS, et al: Naringenin derivatives as anti-atherogenic agents. Bioorg Med Chem Lett. 13:3901–3903. 2003. View Article : Google Scholar : PubMed/NCBI
13	Totta P, Acconcia F, Leone S, Cardillo I and Marino M: Mechanisms of naringenin-induced apoptotic cascade in cancer cells: involvement of estrogen receptor alpha and beta signalling. IUBMB Life. 56:491–499. 2004. View Article : Google Scholar : PubMed/NCBI
14	Harmon AW and Patel YM: Naringenin inhibits glucose uptake in MCF-7 breast cancer cells: a mechanism for impaired cellular proliferation. Breast Cancer Res Treat. 85:103–110. 2004. View Article : Google Scholar : PubMed/NCBI
15	Gao K, Henning SM, Niu Y, et al: The citrus flavonoid naringenin stimulates DNA repair in prostate cancer cells. J Nutr Biochem. 17:89–95. 2006. View Article : Google Scholar
16	Kanno S, Tomizawa A, Hiura T, et al: Inhibitory effects of naringenin on tumor growth in human cancer cell lines and sarcoma S-180-implanted mice. Biol Pharm Bull. 28:527–530. 2005. View Article : Google Scholar : PubMed/NCBI
17	Sanderson JT, Hordijk J, Denison MS, Springsteel MF, Nantz MH and van den Berg M: Induction and inhibition of aromatase (CYP19) activity by natural and synthetic flavonoid compounds in H295R human adrenocortical carcinoma cells. Toxicol Sci. 82:70–79. 2004. View Article : Google Scholar : PubMed/NCBI
18	Chen YC, Shen SC and Lin HY: Rutinoside at C7 attenuates the apoptosis-inducing activity of flavonoids. Biochem Pharmacol. 66:1139–1150. 2003. View Article : Google Scholar : PubMed/NCBI
19	Kanno S, Shouji A, Hirata R, Asou K and Ishikawa M: Effects of naringin on cytosine arabinoside (Ara-C)-induced cytotoxicity and apoptosis in P388 cells. Life Sci. 75:353–365. 2004. View Article : Google Scholar : PubMed/NCBI
20	Lozzio CB and Lozzio BB: Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. Blood. 45:321–334. 1975.PubMed/NCBI
21	Gewirtz AM, Burger D, Rado TA, Benz EJ Jr and Hoffman R: Constitutive expression of platelet glycoproteins by the human leukemia cell line K562. Blood. 60:785–789. 1982.PubMed/NCBI
22	Iwabuchi K, Nagaoka I, Someya A and Yamashita T: Type IV collagen-binding proteins of neutrophils: possible involvement of L-selectin in the neutrophil binding to type IV collagen. Blood. 87:365–372. 1996.PubMed/NCBI
23	Dalrymple S, Antony L, Xu Y, et al: Role of notch-1 and E-cadherin in the differential response to calcium in culturing normal versus malignant prostate cells. Cancer Res. 65:9269–9279. 2005. View Article : Google Scholar : PubMed/NCBI
24	Jeon SM, Kim HK, Kim HJ, et al: Hypocholesterolemic and antioxidative effects of naringenin and its two metabolites in high-cholesterol fed rats. Translat Res. 149:15–21. 2007. View Article : Google Scholar
25	Dieckman LM, Freudenthal BD and Washington MT: PCNA structure and function: insights from structures of PCNA complexes and post-translationally modified PCNA. Subcell Biochem. 62:281–299. 2012. View Article : Google Scholar : PubMed/NCBI
26	Gehen SC, Vitiello PF, Bambara RA, Keng PC and O’Reilly MA: Downregulation of PCNA potentiates p21-mediated growth inhibition in response to hyperoxia. Am J Physiol Lung Cell Mol Physiol. 292:L716–L724. 2007. View Article : Google Scholar
27	Pedraza-Fariña LG: Mechanisms of oncogenic cooperation in cancer initiation and metastasis. Yale J Biol Med. 79:95–103. 2006.
28	Croce CM: Oncogenes and cancer. New Engl J Med. 358:502–511. 2008. View Article : Google Scholar : PubMed/NCBI
29	Lee EW, Lee MS, Camus S, et al: Differential regulation of p53 and p21 by MKRN1 E3 ligase controls cell cycle arrest and apoptosis. EMBO J. 28:2100–2113. 2009. View Article : Google Scholar : PubMed/NCBI
30	Gartel AL and Radhakrishnan SK: Lost in transcription: p21 repression, mechanisms, and consequences. Cancer Res. 65:3980–3985. 2005. View Article : Google Scholar : PubMed/NCBI
31	Insinga A, Cicalese A, Faretta M, et al: DNA damage in stem cells activates p21, inhibits p53, and induces symmetric self-renewing divisions. Proc Natl Acad Sci USA. 110:3931–3936. 2013. View Article : Google Scholar : PubMed/NCBI
32	Panno ML, Giordano F, Mastroianni F, et al: Evidence that low doses of Taxol enhance the functional transactivatory properties of p53 on p21 waf promoter in MCF-7 breast cancer cells. FEBS Lett. 580:2371–2380. 2006. View Article : Google Scholar : PubMed/NCBI
33	Almond JB and Cohen GM: The proteasome: a novel target for cancer chemotherapy. Leukemia. 16:433–443. 2002. View Article : Google Scholar : PubMed/NCBI
34	Chinery R, Brockman JA, Peeler MO, Shyr Y, Beauchamp RD and Coffey RJ: Antioxidants enhance the cytotoxicity of chemotherapeutic agents in colorectal cancer: a p53-independent induction of p21WAF1/CIP1 via C/EBPbeta. Nat Med. 3:1233–1241. 1997. View Article : Google Scholar : PubMed/NCBI
35	Waldman T, Zhang Y, Dillehay L, et al: Cell-cycle arrest versus cell death in cancer therapy. Nat Med. 3:1034–1036. 1997. View Article : Google Scholar : PubMed/NCBI
36	Wu Q, Kirschmeier P, Hockenberry T, et al: Transcriptional regulation during p21WAF1/CIP1-induced apoptosis in human ovarian cancer cells. J Biol Chem. 277:36329–36337. 2002. View Article : Google Scholar : PubMed/NCBI
37	Rodriguez R and Meuth M: Chk1 and p21 cooperate to prevent apoptosis during DNA replication fork stress. Mol Biol Cell. 17:402–412. 2006. View Article : Google Scholar :
38	Rodriguez RJ, Miranda CL, Stevens JF, Deinzer ML and Buhler DR: Influence of prenylated and non-prenylated flavonoids on liver microsomal lipid peroxidation and oxidative injury in rat hepatocytes. Food Chem Toxicol. 39:437–445. 2001. View Article : Google Scholar : PubMed/NCBI
39	Lee MK, Bok SH, Jeong TS, et al: Supplementation of naringenin and its synthetic derivative alters antioxidant enzyme activities of erythrocyte and liver in high cholesterol-fed rats. Bioorg Med Chem. 10:2239–2244. 2002. View Article : Google Scholar : PubMed/NCBI
40	Harrison C: Anticancer drugs: A double strike at kinases. Nature reviews Drug Discov. 9:2702010. View Article : Google Scholar
41	van Acker FA, Schouten O, Haenen GR, van der Vijgh WJ and Bast A: Flavonoids can replace alpha-tocopherol as an antioxidant. FEBS Lett. 473:145–148. 2000. View Article : Google Scholar : PubMed/NCBI
42	Badary OA, Abdel-Maksoud S, Ahmed WA and Owieda GH: Naringenin attenuates cisplatin nephrotoxicity in rats. Life Sci. 76:2125–2135. 2005. View Article : Google Scholar : PubMed/NCBI
43	Arafa HM, Abd-Ellah MF and Hafez HF: Abatement by naringenin of doxorubicin-induced cardiac toxicity in rats. J Egypt Natl Canc Inst. 17:291–300. 2005.